샘플 요청 목록

 카트 문의
시장보고서
상품코드
1874529

세계의 안과용 의약품 시장

Ophthalmic Pharmaceutical Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 272 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 안과용 의약품 시장은 2030년까지 1,025억 달러에 달할 전망

2024년에 830억 달러로 추정되는 세계의 안과용 의약품 시장은 2024-2030년의 분석 기간에 CAGR 3.6%로 성장하며, 2030년까지 1,025억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석 대상 부문의 하나인 항VEGF제는 4.4%의 CAGR을 기록하며, 분석 기간 종료시까지 343억 달러에 달할 것으로 예측됩니다. 항녹내장약 부문의 성장률은 분석 기간에 2.7%의 CAGR로 추정되고 있습니다.

미국 시장은 221억 달러로 추정되는 한편, 중국은 6.3%의 CAGR로 성장할 것으로 예측됩니다.

미국의 안과용 의약품 시장은 2024년에 221억 달러로 추정되고 있습니다. 세계 2위의 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 6.3%로 추이하며, 2030년까지 예측 시장 규모 214억 달러에 달할 것으로 전망되고 있습니다. 기타 주목할 만한 지역별 시장 분석으로는 일본과 캐나다를 들 수 있으며, 분석 기간 중 각각 CAGR 0.7%, 4.3%로 성장할 것으로 예측됩니다. 유럽에서는 독일이 약 1.6%의 CAGR로 성장할 것으로 예측됩니다.

세계 안과의 약품 시장 - 주요 시장 동향과 촉진요인의 개요

안과용 의약품이란 무엇이며, 왜 중요한가?

안과용 의약품은 녹내장, 안구건조증, 감염성 질환, 염증성 질환 등 다양한 안과 질환 및 병증을 치료하기 위해 사용되는 특수 의약품입니다. 이 약물들은 눈에 직접 투여하도록 설계되어 전신 노출을 최소화한 표적 치료가 가능하여 부작용을 줄일 수 있습니다. 안과용 의약품에는 항생제, 항진균제, 항염증약, 노화황반변성(AMD), 당뇨망막병증 등 만성질환 치료제 등이 포함됩니다. 전 세계에서 안질환 발생률이 증가하는 가운데, 이들 의약품은 시력 유지와 안질환 환자의 삶의 질 향상에 중요한 역할을 하고 있습니다.

의학 연구의 발전은 안과 의약품 분야에 어떤 영향을 미치고 있는가?

의학 연구의 발전은 새롭고 효과적인 안과용 의약품의 개발에 큰 영향을 미치고 있습니다. 최근 주요 안질환의 병태생리에 대한 이해의 진전은 이러한 질환에 관여하는 특정 분자 경로를 표적으로 하는 의약품의 혁신을 가져왔습니다. 예를 들어 항VEGF(혈관내피성장인자) 치료는 망막의 비정상적인 혈관 성장을 억제함으로써 노화성 황반변성(AMD), 당뇨성 황반부종 등의 질환 치료에 혁명을 일으켰습니다. 또한 서방형 임플란트, 나노테크놀러지 기반 시스템 등 약물전달 기술의 발전은 약물의 흡수를 촉진하고 작용 시간을 연장하여 치료 효과를 향상시키고 있으며, 특히 장기적인 관리가 필요한 만성질환에서 그 효과가 더욱 두드러지게 나타나고 있습니다.

안과 의약품 산업을 이끄는 동향은 무엇인가?

안과 의약품 산업을 주도하는 몇 가지 주요 동향이 있습니다. 전 세계에서 고령화가 주요 요인으로 작용하고 있으며, 노인은 녹내장, 노화성 황반변성 등 다양한 안과 질환에 걸릴 위험이 높습니다. 이러한 인구 통계학적 변화는 안과 치료에 대한 수요를 증가시켜 시장 성장을 가속하고 있습니다. 또한 최소침습적 치료에 대한 선호도가 높아지면서 기존 수술에 대한 대안을 제공하는 첨단 약물전달 시스템의 개발이 촉진되고 있습니다. 전 세계에서 당뇨병 환자가 증가함에 따라 당뇨병성 망막증 발병률도 증가하고 있으며, 효과적인 치료법의 필요성이 더욱 커지고 있습니다. 또한 인식의 향상과 진단 기술의 발전으로 안과 질환의 조기 발견 및 치료가 가능해지면서 안과용 의약품에 대한 수요가 더욱 증가하고 있습니다.

안과용 의약품 시장의 성장을 이끄는 요인은 무엇인가?

안과 의약품 시장의 성장은 치료 효과와 환자 순응도를 향상시키는 약물 개발 및 전달 시스템의 기술적 진보를 포함한 여러 요인에 의해 촉진되고 있습니다. 전 세계에서 만성 안질환에 취약한 고령 인구 증가는 안과 의약품 수요 증가에 크게 기여하고 있습니다. 또한 심각한 안과적 합병증을 동반하는 당뇨병과 같은 만성질환이 전 세계에서 증가하고 있는 것도 시장 성장을 촉진하고 있습니다. 소비자의 행동은 회복이 빠르고 부작용이 적으며, 덜 침습적인 첨단 치료법을 선호하는 방향으로 변화하고 있으며, 이는 혁신적인 안과용 의약품의 채택을 촉진하고 있습니다. 마지막으로 눈 건강에 대한 인식을 높이고 안과 치료에 대한 접근성을 개선하기 위한 정부 및 비정부기구의 노력은 시장 확대에 중요한 역할을 하고 있으며, 이러한 중요한 의약품에 대한 지속적인 수요를 보장하고 있습니다.

부문 :

약제 분류(항VEGF제, 항녹내장약, 항염증약, 항알레르기약, 기타 약제 분류), 유형(처방약, 시판약)

조사 대상 기업의 예

  • Allergan PLC
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Johnson and Johnson Vision Care Inc
  • Kyowa Kirin Co., Ltd
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceuticals Co., Ltd.
  • Shire PLC

AI 통합

검증된 전문가 컨텐츠와 AI 툴을 통해 시장 및 경쟁 정보 분석 방식을 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM(거대 언어 모델)이나 산업별 SLM(소규모 언어 모델)에 대한 쿼리 방식에 의존하는 대신, 전 세계 도메인 전문가들이 엄선한 컨텐츠 리포지토리를 구축했습니다. 여기에는 비디오 전사, 블로그, 검색엔진 조사, 그리고 방대한 양의 기업, 제품/서비스, 시장 데이터가 포함됩니다.

관세 영향 계수

이번 보고서에는 Global Industry Analysts가 예측한 본사 소재지, 생산기지, 수출입(완제품 및 OEM)에 따른 기업의 경쟁력 변화에 따라 지역 시장에 미치는 관세의 영향을 반영했습니다. 이러한 복잡하고 다면적인 시장 현실은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학을 통해 경쟁사들에게 영향을 미칠 것입니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA

Global Ophthalmic Pharmaceutical Drugs Market to Reach US$102.5 Billion by 2030

The global market for Ophthalmic Pharmaceutical Drugs estimated at US$83.0 Billion in the year 2024, is expected to reach US$102.5 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Anti-VEGF Agents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$34.3 Billion by the end of the analysis period. Growth in the Anti-Glaucoma segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$22.1 Billion While China is Forecast to Grow at 6.3% CAGR

The Ophthalmic Pharmaceutical Drugs market in the U.S. is estimated at US$22.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$21.4 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Ophthalmic Pharmaceutical Drugs Market - Key Trends & Drivers Summarized

What Are Ophthalmic Pharmaceutical Drugs and Why Are They Important?

Ophthalmic pharmaceutical drugs are specialized medications used to treat various eye conditions and diseases such as glaucoma, dry eye syndrome, infections, and inflammatory disorders. These drugs are formulated to be administered directly into the eye, ensuring targeted therapy with minimal systemic exposure, which can lead to reduced side effects. The range of ophthalmic drugs includes antibiotics, antifungal, anti-inflammatory agents, and treatments for chronic conditions like age-related macular degeneration (AMD) and diabetic retinopathy. With the rising incidence of eye-related ailments globally, these drugs play a critical role in preserving vision and improving the quality of life for patients suffering from ocular diseases.

How Are Advances in Medical Research Shaping the Ophthalmic Drugs Sector?

Advancements in medical research have significantly influenced the development of new and more effective ophthalmic drugs. Recent breakthroughs in understanding the pathophysiology of major eye diseases have led to the innovation of drugs that target specific molecular pathways involved in these conditions. For example, anti-VEGF (Vascular Endothelial Growth Factor) therapy has revolutionized the treatment of diseases like AMD and diabetic macular edema by inhibiting the growth of abnormal blood vessels in the retina. Additionally, advancements in drug delivery technology, such as sustained release implants and nanotechnology-based systems, have improved the efficacy of treatments by enhancing drug absorption and prolonging the duration of action, which is particularly beneficial for chronic diseases that require long-term management.

What Trends Are Driving the Ophthalmic Pharmaceutical Drugs Industry?

Several key trends are driving the ophthalmic pharmaceutical drugs industry. An aging global population is a major factor, as older individuals are at a higher risk for developing many types of eye diseases, including glaucoma and AMD. This demographic shift is increasing the demand for ophthalmic treatments and driving growth in the market. Furthermore, there is an increasing preference for minimally invasive treatments, which has spurred the development of advanced drug delivery systems that offer alternatives to traditional surgeries. The rise in prevalence of diabetes worldwide has also escalated the incidence of diabetic retinopathy, prompting a greater need for effective therapeutic interventions. Additionally, increased awareness and improved diagnostic techniques are enabling earlier detection and treatment of eye conditions, further propelling the demand for ophthalmic drugs.

What Drives the Growth of the Ophthalmic Pharmaceutical Drugs Market?

The growth in the ophthalmic pharmaceutical drugs market is driven by several factors, including technological advancements in drug development and delivery systems that enhance treatment efficacy and patient compliance. The expanding geriatric population globally, which is more susceptible to chronic eye conditions, significantly contributes to the increasing demand for ophthalmic medications. Moreover, the global increase in chronic diseases such as diabetes, which are often associated with serious eye complications, also boosts the market growth. Consumer behavior is shifting towards preferring advanced, less invasive treatment options that offer quicker recovery and fewer side effects, which in turn drives the adoption of innovative ophthalmic drugs. Lastly, governmental and non-governmental efforts to raise awareness about eye health and improve accessibility to ophthalmic treatments play crucial roles in the market expansion, ensuring a sustained demand for these vital medications.

SCOPE OF STUDY:

The report analyzes the Ophthalmic Pharmaceutical Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy, Other Drug Classes); Type (Prescription Drugs, Over-the-Counter Drugs)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Allergan PLC
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Johnson and Johnson Vision Care Inc
  • Kyowa Kirin Co., Ltd
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceuticals Co., Ltd.
  • Shire PLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Ophthalmic Pharmaceutical Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Drug Delivery Systems Propel Growth in Ophthalmic Pharmaceutical Drugs Market
    • Increasing Prevalence of Eye Disorders Expands Addressable Market Opportunity
    • Technological Innovations in Formulations Generate Demand for Advanced Ophthalmic Drugs
    • Growth in Geriatric Population Drives Adoption of Ophthalmic Pharmaceuticals
    • Rising Awareness of Eye Health Strengthens Business Case for Preventative Treatments
    • Adoption of Biologics and Biosimilars Spurs Growth in Ophthalmic Drug Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ophthalmic Pharmaceutical Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anti-VEGF Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anti-VEGF Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Anti-VEGF Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anti-Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anti-Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Anti-Glaucoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-Inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-Inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Anti-Inflammatory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Anti-Allergy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Anti-Allergy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Anti-Allergy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Over-the-Counter Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Over-the-Counter Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Over-the-Counter Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • JAPAN
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • CHINA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • EUROPE
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • FRANCE
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • GERMANY
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • INDIA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • AFRICA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제